C Lualdi1, A Silverii1, I Dicembrini1, L Pala1, M Monami1, E Mannucci2. 1. Diabetology, Azienda Ospedaliero Universitaria Careggi and University of Florence, 50141, Florence, Italy. 2. Diabetology, Azienda Ospedaliero Universitaria Careggi and University of Florence, 50141, Florence, Italy. edoardo.mannucci@unifi.it.
Abstract
BACKGROUND: Degludec is a long-acting insulin with a longer duration of action and a greater day-to-day reproducibility of absorption in comparison with previous long-acting insulin formulations. The aim is the definition of the change in insulin needs in patients switching from detemir/glargine to degludec in real-life conditions. METHODS: In this retrospective cohort observational study, all outpatients with either type 1 or type 2 diabetes, starting therapy with degludec insulin-after a prior treatment with either detemir or glargine insulin for at least 6 months-were included. RESULTS: The analysis was performed on 266 patients, 172 and 96 with type 1 and type 2 diabetes, respectively. The equations describing the relationship between baseline and follow-up doses of basal insulin (6 months) were Y = 3.39 + 0.78X and Y = 0.44 + 0.69X, in patients receiving detemir/glargine either once or twice daily, respectively (Y = degludec dose at 6 months and X = basal insulin dose at switch). The corresponding equations for prandial insulin doses were y = 1.83 + 0.83*x and y = 2.85 + 0.80*x for those on pre-switch once or twice-daily basal insulin, respectively. In type 2 diabetes, the switch was associated with a reduction of basal insulin doses only in those with a prior twice-daily treatment with basal insulin. The reduction of prandial insulin reached statistical significance only in patients previously treated with basal insulin once daily. CONCLUSIONS: The present results provide a suggestion for a simple method for the adjustment of basal and prandial insulin doses in type 1 diabetic patients, switching from glargine or detemir to degludec.
BACKGROUND:Degludec is a long-acting insulin with a longer duration of action and a greater day-to-day reproducibility of absorption in comparison with previous long-acting insulin formulations. The aim is the definition of the change in insulin needs in patients switching from detemir/glargine to degludec in real-life conditions. METHODS: In this retrospective cohort observational study, all outpatients with either type 1 or type 2 diabetes, starting therapy with degludecinsulin-after a prior treatment with either detemir or glargineinsulin for at least 6 months-were included. RESULTS: The analysis was performed on 266 patients, 172 and 96 with type 1 and type 2 diabetes, respectively. The equations describing the relationship between baseline and follow-up doses of basal insulin (6 months) were Y = 3.39 + 0.78X and Y = 0.44 + 0.69X, in patients receiving detemir/glargine either once or twice daily, respectively (Y = degludec dose at 6 months and X = basal insulin dose at switch). The corresponding equations for prandial insulin doses were y = 1.83 + 0.83*x and y = 2.85 + 0.80*x for those on pre-switch once or twice-daily basal insulin, respectively. In type 2 diabetes, the switch was associated with a reduction of basal insulin doses only in those with a prior twice-daily treatment with basal insulin. The reduction of prandial insulin reached statistical significance only in patients previously treated with basal insulin once daily. CONCLUSIONS: The present results provide a suggestion for a simple method for the adjustment of basal and prandial insulin doses in type 1 diabeticpatients, switching from glargine or detemir to degludec.
Entities:
Keywords:
Basal insulin; Degludec; Insulin; Prandial insulin; Type 1 diabetes; Type 2 diabetes
Authors: A Dornhorst; H-J Lüddeke; S Sreenan; C Koenen; J B Hansen; A Tsur; L Landstedt-Hallin Journal: Int J Clin Pract Date: 2007-03 Impact factor: 2.503
Authors: Jeremy Pettus; Tricia Santos Cavaiola; William V Tamborlane; Steven Edelman Journal: Diabetes Metab Res Rev Date: 2015-11-25 Impact factor: 4.876
Authors: A C R Simon; J E Schopman; J B L Hoekstra; A Abu-Hanna; V E A Gerdes; N Peek; F Holleman Journal: Diabet Med Date: 2014-10-11 Impact factor: 4.359
Authors: M J Davies; J L Gross; Y Ono; T Sasaki; G Bantwal; M A Gall; M Niemeyer; H Seino Journal: Diabetes Obes Metab Date: 2014-05-08 Impact factor: 6.577
Authors: Florentino Carral San Laureano; Mariana Tomé Fernández-Ladreda; Ana Isabel Jiménez Millán; Concepción García Calzado; María Del Carmen Ayala Ortega Journal: J Investig Med Date: 2021-03-26 Impact factor: 2.895
Authors: Paola Ponzani; Cesare Berra; Alessandra Di Lelio; Paola Del Sindaco; Chiara Di Loreto; Francesco Reggiani; Giuseppe Lucisano; Maria Chiara Rossi Journal: Diabetes Ther Date: 2019-11-09 Impact factor: 2.945